<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alagille syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alagille syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Alagille syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Taisa J Kohut, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathleen M Loomes, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3362375017"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alagille syndrome is a genetic disorder that primarily causes cholestatic liver disease but is also associated with defects in multiple other organ systems. The clinical manifestations and severity vary widely even among individuals within the same family.</p><p>The clinical manifestations, diagnosis, and management of Alagille syndrome are discussed below. Related content is available in other topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5941.html" rel="external">"Approach to evaluation of cholestasis in neonates and young infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia"</a>.)</p><p></p><p class="headingAnchor" id="H2638204069"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Reported incidence rates of Alagille syndrome are between 1:70,000 and 1:100,000 live births. With increased case detection due to molecular diagnosis, the true incidence is probably closer to 1 in 30,000 [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2473790050"><span class="h1">GENETICS AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Alagille syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F118450&amp;token=87jLzclRwWxNoI%2BQq5Gg74V%2B2jCt4LsL%2BB%2BnqBwfLwgoe8ZNZ6oKZP7lpXiwtvuo&amp;TOPIC_ID=139432" target="_blank">MIM #118450</a>) is inherited in an autosomal dominant fashion. Pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601920&amp;token=87jLzclRwWxNoI%2BQq5Gg774xSAoGh1xfv48zrsTU3sqguhOZACU1cxJ%2FJwdr%2BZkS&amp;TOPIC_ID=139432" target="_blank"><i>JAG1</i></a> gene on chromosome 20p12 are responsible for Alagille syndrome in almost 95 percent of patients. A small percentage (approximately 2.5 percent) have pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600275&amp;token=87jLzclRwWxNoI%2BQq5Gg71ccfWEtTEKgWzBy1w8isFuHtnp%2FqS2XEbs6LYvN1tod&amp;TOPIC_ID=139432" target="_blank"><i>NOTCH2</i></a> gene. These genes encode a ligand and receptor, respectively, in the Notch signaling pathway, which is involved in development and function of multiple organs [<a href="#rid2">2</a>].</p><p>More than 600 pathogenic <em>JAG1</em> variants and 20 <em>NOTCH2</em> variants have been reported for Alagille syndrome [<a href="#rid3">3</a>]. The <em>JAG1</em> variants tend to be protein-truncating variants, and a disease pathomechanism of haploinsufficiency has been proposed [<a href="#rid4">4-6</a>]. The <em>NOTCH2</em> variants tend to be predominantly missense, and the mechanism for pathogenicity has not been confirmed [<a href="#rid7">7,8</a>]. The clinical features and severity vary widely even among individuals within the same family or with the same identified variant [<a href="#rid2">2</a>]. This suggests a role for variants in other gene(s) that modify the effects of the <em>JAG1</em> pathogenic variants, and several candidate genetic modifiers have been proposed [<a href="#rid9">9-12</a>].</p><p>In approximately 3.4 percent of individuals with a confident clinical diagnosis of Alagille syndrome, standard genetic testing detects no pathogenic variants of <em>JAG1</em> or <em>NOTCH2</em>. Utilization of genome sequencing reduces the percentage of individuals without a molecular diagnosis to 2.5 percent [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H2627107342"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Alagille syndrome affects multiple organ systems and has a wide range of clinical severity, ranging from life-threatening liver or cardiac disease to only subclinical manifestations. Individuals with severe liver or cardiac manifestations typically present in infancy. Those who present after the neonatal period tend to have a milder course and may not be diagnosed until later in childhood or even adulthood [<a href="#rid14">14</a>].</p><p>The clinical features of Alagille syndrome are summarized in the table  (<a class="graphic graphic_table graphicRef141282" href="/z/d/graphic/141282.html" rel="external">table 1</a>) and described below [<a href="#rid14">14-18</a>].</p><p class="headingAnchor" id="H2043391230"><span class="h2">Cholestatic liver disease</span><span class="headingEndMark"> — </span>Cholestatic liver disease is one of the most common features of Alagille syndrome [<a href="#rid18">18</a>]. It typically presents in the neonatal period with direct hyperbilirubinemia and has variable severity and clinical course. In some infants, the liver disease improves during early childhood and is unlikely to recur later in life. In others, the liver disease progressively worsens during early childhood [<a href="#rid14">14,16</a>]. Although the clinical course is difficult to predict, more severe cholestasis (total bilirubin &gt;6.5 mg/dL, conjugated bilirubin &gt;4.5 mg/dL, and cholesterol &gt;520 mg/dL) in a young child is associated with sustained and more severe liver disease [<a href="#rid19">19</a>]. In infants 6 to 12 months old, median total bilirubin levels are correlated with the risk of developing clinically evident portal hypertension [<a href="#rid20">20</a>]. The frequency of hepatic disease is high in case series in which Alagille syndrome is identified by symptoms and much lower when cases are identified by genetic screening of family members [<a href="#rid1">1</a>].</p><p>Important clinical consequences of severe cholestatic liver disease include pruritus (which is often debilitating), xanthomas, fat-soluble vitamin deficiency, malnutrition and growth failure, and cirrhosis with portal hypertension. (See <a class="local">'Medical management'</a> below.)</p><p>The most consistently reported histologic feature of Alagille syndrome is bile duct paucity (defined as having a bile duct-to-portal tract ratio &lt;0.5, compared with normal ratio ranges from 0.9 to 1.8), but this feature may not be detectable prior to six months of age [<a href="#rid16">16,21</a>]. Other histologic features including ductular proliferation and giant cell hepatitis can be present in infancy, and liver biopsies with these features may be difficult to distinguish from biliary atresia.</p><p class="headingAnchor" id="H1971162132"><span class="h2">Congenital heart disease</span><span class="headingEndMark"> — </span>Congenital heart disease is common in Alagille syndrome. The most common finding is stenosis/hypoplasia of the branch pulmonary arteries; other anomalies include tetralogy of Fallot, patent ductus arteriosus, septal defects, or coarctation of the aorta [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H2265489805"><span class="h2">Vascular anomalies</span><span class="headingEndMark"> — </span>Vascular anomalies are common in Alagille syndrome and can lead to significant morbidity and mortality [<a href="#rid23">23</a>]. Up to one-quarter of individuals with Alagille syndrome have intracranial bleeds, and the vast majority have no other risk factors [<a href="#rid24">24</a>]. Both arterial and venous anomalies have been reported [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H2633667694"><span class="h2">Other features</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney disease</strong> – Renal abnormalities are present in some individuals with Alagille syndrome and may include renal dysplasia (most common), glomerular mesangiolipidosis, or renal tubular acidosis [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skeletal anomalies</strong> – Butterfly vertebrae are the most common skeletal abnormalities in Alagille syndrome. This finding has no structural significance, and patients are asymptomatic [<a href="#rid27">27</a>]. Various other skeletal abnormalities can occur, including temporal bone abnormalities and middle ear bone defects, which can lead to chronic otitis media and hearing loss [<a href="#rid28">28</a>]. There is also an increased risk of long bone fragility fracture due to the nutritional consequences of cholestasis as well as the skeletal effects of the intrinsic genetic and hormonal disturbances in people with Alagille syndrome [<a href="#rid29">29</a>]. Unilateral coronal craniosynostosis has also been reported in patients with Alagille syndrome and pathogenic variants in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601920&amp;token=87jLzclRwWxNoI%2BQq5Gg774xSAoGh1xfv48zrsTU3sqguhOZACU1cxJ%2FJwdr%2BZkS&amp;TOPIC_ID=139432" target="_blank"><i>JAG1</i></a> [<a href="#rid30">30,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Facies</strong> – Dysmorphic facies noted in many infants consist of a broad nasal bridge, triangular facies (broad forehead and pointed chin), and deep-set eyes  (<a class="graphic graphic_picture graphicRef53349" href="/z/d/graphic/53349.html" rel="external">picture 1</a>). These features change over time to a prominent lower face and mandible and less prominent upper face and forehead [<a href="#rid32">32</a>]. This is the clinical feature with the highest penetrance, with almost universal occurrence in <em>JAG1</em> mutation-positive probands and relatives [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ophthalmologic abnormalities</strong> – Posterior embryotoxon (a prominent Schwalbe ring) is the most common ocular feature in Alagille syndrome, although it is also common in the general population. Optic disc drusen may be more specific for diagnosis [<a href="#rid33">33</a>]. Other findings may include hypopigmentation of the peripheral retina, pseudopapilledema, and true papilledema (associated with intracranial hypertension) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth failure</strong> – Growth failure is common in Alagille syndrome. More than one-half of patients have height and/or weight below the 5<sup>th</sup> percentile for their age [<a href="#rid2">2,35</a>]. The growth failure is likely multifactorial; it may be related to malabsorption (due to cholestasis), the underlying genetic defects, or, possibly, to growth hormone insensitivity [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognition</strong> <strong>and psychosocial function</strong> – Almost one-half of children with cholestatic Alagille syndrome have neurocognitive deficits and the need for special education. In a multicenter study, children with Alagille syndrome had slightly lower full-scale intelligence quotient scores compared with those with progressive familial intrahepatic cholestasis or alpha-1 antitrypsin deficiency [<a href="#rid38">38</a>]. Furthermore, some individuals experience impaired quality of life and mental health issues related to intractable pruritus and xanthomas [<a href="#rid39">39,40</a>].</p><p></p><p class="headingAnchor" id="H363330138"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Most patients with Alagille syndrome present with cholestatic jaundice during early infancy [<a href="#rid14">14</a>]. A minority present later in infancy or childhood with signs of cholestatic liver disease (jaundice, pruritus) or are identified by genetic screening because a sibling or parent has known Alagille syndrome. The focus and extent of the evaluation depends on the clinical presentation:</p><p class="headingAnchor" id="H118342954"><span class="h2">Cholestatic infants: Exclude biliary atresia</span><span class="headingEndMark"> — </span>For cholestatic infants, the first priority is to evaluate for biliary atresia. Biliary atresia is the most common cause of cholestatic liver disease in young infants, and outcomes depend on prompt diagnosis and treatment. Diagnosis and management of biliary atresia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia"</a>.)</p><p>If biliary atresia is excluded, the infant should be evaluated for Alagille syndrome and other causes of neonatal cholestasis. (See  <a class="medical medical_review" href="/z/d/html/5941.html" rel="external">"Approach to evaluation of cholestasis in neonates and young infants"</a> and  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p class="headingAnchor" id="H2937699238"><span class="h2">Family members of a proband: Start with genetic testing</span><span class="headingEndMark"> — </span>For asymptomatic first-degree relatives of a proband with Alagille syndrome (parents or siblings), an efficient approach is to start with genetic testing. If genetic testing reveals a pathogenic variant in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601920&amp;token=87jLzclRwWxNoI%2BQq5Gg774xSAoGh1xfv48zrsTU3sqguhOZACU1cxJ%2FJwdr%2BZkS&amp;TOPIC_ID=139432" target="_blank"><i>JAG1</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600275&amp;token=87jLzclRwWxNoI%2BQq5Gg71ccfWEtTEKgWzBy1w8isFuHtnp%2FqS2XEbs6LYvN1tod&amp;TOPIC_ID=139432" target="_blank"><i>NOTCH2</i></a>, then the patient should have a full evaluation for associated anomalies, as outlined below. (See <a class="local">'Genetic testing'</a> below.)</p><p class="headingAnchor" id="H2181929583"><span class="h2">All ages: Evaluate for associated anomalies</span><span class="headingEndMark"> — </span>Patients with suspected or confirmed Alagille syndrome should be evaluated for the presence and severity of associated anomalies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>General – Complete blood count, electrolytes, blood urea nitrogen, creatinine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver function and cholestasis – Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase, coagulation studies, total and direct bilirubin, serum cholesterol, triglycerides, serum bile acids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – Usually performed during the initial evaluation, although results may not be immediately available. (See <a class="local">'Genetic testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver ultrasound</p><p class="bulletIndent2"><span class="glyph">•</span>Renal ultrasound</p><p class="bulletIndent2"><span class="glyph">•</span>Spine radiograph (anteroposterior)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specialty evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatology evaluation – This may include liver biopsy, depending on the clinical scenario. For example, in a cholestatic infant, a liver biopsy may be required to make a timely diagnosis of biliary atresia, rather than waiting for results of genetic tests for Alagille syndrome. (See  <a class="medical medical_review" href="/z/d/html/5941.html" rel="external">"Approach to evaluation of cholestasis in neonates and young infants"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiology evaluation – Including echocardiogram. (See  <a class="medical medical_review" href="/z/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic evaluation – Specifically for posterior embryotoxon, optic Drusen, and papilledema.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nutritional assessment – Including evaluation for fat-soluble vitamin deficiencies in those with cholestatic liver disease.</p><p></p><p class="headingAnchor" id="H3203496155"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Alagille syndrome is suspected in individuals who present with suggestive features (especially otherwise unexplained cholestatic liver disease)  (<a class="graphic graphic_table graphicRef141282" href="/z/d/graphic/141282.html" rel="external">table 1</a>) or those with a first-degree relative with Alagille syndrome. The diagnosis should be confirmed by genetic testing whenever possible. Occasionally, the diagnosis is made based on clinical criteria alone.</p><p class="headingAnchor" id="H1189956280"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>The diagnosis of Alagille syndrome is confirmed by genetic testing, usually with next-generation sequencing (NGS) panels for cholestatic liver disease. The vast majority of individuals with Alagille syndrome have a heterozygous autosomal dominant pathogenic variant in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601920&amp;token=87jLzclRwWxNoI%2BQq5Gg774xSAoGh1xfv48zrsTU3sqguhOZACU1cxJ%2FJwdr%2BZkS&amp;TOPIC_ID=139432" target="_blank"><i>JAG1</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600275&amp;token=87jLzclRwWxNoI%2BQq5Gg71ccfWEtTEKgWzBy1w8isFuHtnp%2FqS2XEbs6LYvN1tod&amp;TOPIC_ID=139432" target="_blank"><i>NOTCH2</i></a> (see <a class="local">'Genetics and pathogenesis'</a> above). Genomic diagnostics typically include sequencing and deletion/duplication testing of <em>JAG1</em> and <em>NOTCH2</em>. The interpretation and characterization of variants of uncertain significance in <em>JAG1</em> and <em>NOTCH2</em> can be challenging, especially with the widespread use of NGS panels. Information about genetic testing and a clinical review are available at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=139432" target="_blank">Genetic Testing Registry website</a>.</p><p>Occasionally, genetic testing confirms a diagnosis of Alagille syndrome despite few or no clinical manifestations of the syndrome; this is more common in individuals with <em>NOTCH2</em> variants but can also occur in those with <em>JAG1</em>-related disease [<a href="#rid1">1,8,41</a>].</p><p class="headingAnchor" id="H1195736896"><span class="h2">Clinical criteria</span><span class="headingEndMark"> — </span>Before the advent of genetic testing, Alagille syndrome was diagnosed clinically, based on the presence of intrahepatic bile duct paucity and at least three other clinical features: chronic cholestasis, cardiac disease, ocular abnormalities, skeletal abnormalities, and/or characteristic facial features. Although not included in the classical clinical criteria, renal and vascular disease are common features. (See <a class="local">'Clinical features'</a> above.)</p><p>Alagille syndrome may be diagnosed based on the above clinical criteria if genetic testing is not available or if genetic testing is negative but the patient has strong clinical features of Alagille syndrome (approximately 2.5 percent of cases). (See <a class="local">'Genetics and pathogenesis'</a> above.)</p><p class="headingAnchor" id="H1400255707"><span class="h2">Differential diagnosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholestatic liver disease</strong> – Biliary atresia is the most common cause of cholestatic liver disease in infants. The clinical features of biliary atresia and Alagille syndrome can be similar, so a high index of suspicion is required to distinguish between these disorders. Infants with biliary atresia classically have absent excretion on hepatobiliary scintigraphy, proliferation of intrahepatic bile ducts on liver biopsy, and cholangiogram that fails to show the intrahepatic tree, but these findings can also be seen in infants with Alagille syndrome. Therefore, it is critical to evaluate all infants with cholestatic liver disease carefully for any syndromic features or a family history of Alagille syndrome and to perform genetic testing if there is any question of Alagille syndrome.</p><p></p><p class="bulletIndent1">The evaluation of an infant presenting with cholestatic liver disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5941.html" rel="external">"Approach to evaluation of cholestasis in neonates and young infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bile duct paucity</strong> – The histologic finding of paucity of interlobular bile ducts found in Alagille syndrome also may be observed in several other cholestatic disorders, including alpha-1 antitrypsin deficiency, cystic fibrosis, infection (eg, cytomegalovirus, syphilis), mitochondrial disorders, progressive familial intrahepatic cholestasis types 1 and 2, or arthrogryposis-renal dysfunction-cholestasis syndrome [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants", section on 'Infectious causes'</a> and  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants", section on 'Genetic/metabolic disorders'</a>.)</p><p></p><p class="bulletIndent1">Occasionally, paucity of the interlobular bile ducts is observed without features of Alagille syndrome or the above disorders, in which case, the disorder is termed "nonsyndromic" paucity of the interlobular bile ducts [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H2609001258"><span class="h1">MEDICAL MANAGEMENT</span><span class="headingEndMark"> — </span>Medical management of patients with Alagille syndrome requires a multidisciplinary approach, tailored to the patient's disease manifestations and severity [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H390546545"><span class="h2">Pruritus</span><span class="headingEndMark"> — </span>Pruritus is a common complication of chronic cholestasis, occurring in 80 percent of patients with Alagille syndrome in one series [<a href="#rid17">17,45</a>]. Pruritus can be severe, has adverse effects on quality of life, and can lead to excoriations. Initial measures to help minimize itching and excoriations include skin emollients, cutting nails short, and avoiding bathing in hot water.</p><p>Medical therapy is required for individuals with problematic pruritus despite the initial measures; available drugs are summarized in the table  (<a class="graphic graphic_table graphicRef141283" href="/z/d/graphic/141283.html" rel="external">table 2</a>). Combinations of these medications are often required and should be added in a stepwise fashion, based on the individual patient's level of symptoms, response, and adverse effects. Our stepwise approach is outlined below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ursodeoxycholic acid</strong><strong> (UDCA)</strong> – We start most patients on UDCA for supportive treatment of chronic cholestasis, and this drug may also be beneficial for cholestatic pruritus. UCDA is a choleretic that stimulates bile flow and is commonly used as a treatment for cholestasis. A small clinical trial suggests that UCDA improves pruritus in approximately one-half of individuals with Alagille syndrome but probably does not alter progression of liver disease [<a href="#rid46">46</a>]. These findings are consistent with our own experience.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antihistamines</strong> – If pruritus is refractory to optimized dosing of UDCA and interferes with sleep, a bedtime dose of an antihistamine (eg, <a class="drug drug_pediatric" data-topicid="13236" href="/z/d/drug information/13236.html" rel="external">diphenhydramine</a> or <a class="drug drug_pediatric" data-topicid="13368" href="/z/d/drug information/13368.html" rel="external">hydroxyzine</a>) can be started and gradually increased to three to four times per day as needed; however, daytime drowsiness may limit the use of these drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rifampin</strong> – If the pruritus remains problematic, we typically add <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> as an adjunct to UDCA (+/- antihistamines). The mechanism for the effect on pruritus may involve modulation of pruritogen-modulating factors that are targeted by the pregnane X receptor (present in both hepatocytes and enterocytes). In a small, open-label trial, rifampin was found to be safe and effective therapy to reduce pruritus in 90 percent of children with chronic cholestasis and severe pruritus unresponsive to other treatments (UDCA, antihistamines) [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ileal bile acid transport (IBAT) inhibitors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maralixibat</strong> – <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">Maralixibat</a> is an IBAT inhibitor that acts on the apical sodium-dependent bile acid transporter. It is a first- or second-line agent for the treatment of cholestatic pruritus in patients with Alagille syndrome and is approved by the US Food and Drug Administration (FDA) for individuals ≥3 months of age [<a href="#rid48">48</a>]. Most clinicians will have likely tried UDCA, antihistamines, and/or <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> prior to escalating to maralixibat due to high cost. Selection of medications may change as data on long-term outcomes accumulate.</p><p></p><p class="bulletIndent2">The starting dose of <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a> is 190 micrograms/kg daily for seven days, and the dose is then increased to 380 micrograms/kg daily (maximum dose 28.5 mg daily) [<a href="#rid48">48</a>]. Maralixibat may be used in combination with UDCA for patients with severe pruritus. It generally should not be used in combination with bile acid sequestrants (which bind maralixibat in the intestinal lumen, thereby inhibiting its activity). If bile acid resins are used, there should be a four-hour gap between their administration and that of maralixibat.</p><p></p><p class="bulletIndent2">Because <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a> inhibits bile acid absorption, it may cause diarrhea due to the effect of the unabsorbed bile salts on colonic epithelium. Additionally, bile salt depletion can cause malabsorption of fat and fat-soluble vitamins (vitamins A, D, E, and K), which may need supplementation. Although maralixibat is poorly absorbed, in some cases, it may exacerbate abnormalities of liver function tests. Therefore, serum bilirubin, alanine and aspartate aminotransferases (ALT and AST), alkaline phosphatase, gamma-glutamyl transferase, and prothrombin time (international normalized ratio) should be monitored at baseline and during the course of therapy.</p><p></p><p class="bulletIndent2">In a combined analysis of two randomized trials and their extensions in 57 children with Alagille syndrome and severe cholestasis, <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a> improved pruritus and quality of life and one-third of participants had complete resolution of pruritus [<a href="#rid49">49</a>]. At week 48, decreases in serum bile acids, cholesterol, and platelet count were noted, while serum ALT increased; nine participants discontinued study drug due to ALT rise or other treatment-emergent events.</p><p></p><p class="bulletIndent2">Long-term outcomes of treatment with <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a> are beginning to emerge. In one study, long-term treatment with maralixibat (84 patients treated for up to six years) was associated with better six-year event-free survival (EFS) compared with 469 untreated patients in a disease registry (71 versus 50 percent; adjusted hazard ratio 0.305, 95% CI 0.189-0.491) [<a href="#rid50">50</a>]. EFS was defined as lack of variceal bleeding, ascites requiring therapy, surgical biliary diversion, liver transplantation, or death. A separate study on the same cohort (76 individuals, mean treatment duration 4.7 years), found that predictors of EFS and transplant-free survival included &gt;1 point improvement in pruritus score, serum bilirubin &lt;6.5 mg/dL, and bile acids &lt;200 micromol/L at week 48, as well as baseline bilirubin [<a href="#rid51">51</a>]. Sixteen participants (21 percent) in this cohort progressed to liver transplant, decompensation, death, or surgical biliary diversion (10, 3, 2, and 1 participants, respectively). These findings suggest that patients who display clinical improvements in these parameters within the first year of maralixibat therapy are more likely to have long-term benefits in EFS and transplant-free survival.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Odevixibat</strong> – <a class="drug drug_pediatric" data-topicid="132117" href="/z/d/drug information/132117.html" rel="external">Odevixibat</a> is another IBAT inhibitor. In a phase 2, open-label study in children with Alagille syndrome and other cholestatic disorders, odevixibat (10 to 200 micrograms/kg daily for four weeks) appeared to reduce serum bile acids and pruritus [<a href="#rid52">52</a>]. In a 24-week trial in children with pruritus and nonsevere cholestatic liver disease due to Alagille syndrome, odevixibat significantly reduced a scratching score (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT04674761&amp;token=Ste%2FJ%2B0Zk8%2BGCpKsBOssVXs7REdxnziGg6IyMw%2BTV0KDbRivO5wpXLhD8Vgeu4G0bMCdq6EqD8oh9gSGTtLHBQ%3D%3D&amp;TOPIC_ID=139432" target="_blank">NCT04674761</a>) [<a href="#rid53">53</a>]. This trial was the basis for the FDA's approval of odevixibat for the treatment of cholestatic pruritus in patients ≥12 months of age with Alagille syndrome. Long-term follow-up studies of odevixibat are ongoing (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT05035030&amp;token=Ste%2FJ%2B0Zk8%2BGCpKsBOssVXs7REdxnziGg6IyMw%2BTV0KDbRivO5wpXLhD8Vgeu4G0bfjWalcOqGjLqJGQhjmEiQ%3D%3D&amp;TOPIC_ID=139432" target="_blank">NCT05035030</a>). Previous experience with odevixibat was for treatment of cholestasis in people with progressive familial intrahepatic cholestasis. (See  <a class="medical medical_review" href="/z/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia", section on 'Progressive familial intrahepatic cholestasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Naltrexone</strong> – <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">Naltrexone</a>, an opioid-antagonist, was also commonly trialed for refractory cholestatic pruritus prior to the availability of <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a> and <a class="drug drug_pediatric" data-topicid="132117" href="/z/d/drug information/132117.html" rel="external">odevixibat</a>. It is somewhat effective for pruritus in cholestatic liver disease, as suggested by several case series and one small randomized trial [<a href="#rid54">54-57</a>]. In our experience, naltrexone is effective in a dose-dependent manner for a subset of patients, using the doses outlined in the table  (<a class="graphic graphic_table graphicRef141283" href="/z/d/graphic/141283.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sertraline</strong> – <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">Sertraline</a>, a serotonin reuptake inhibitor, was commonly trialed for refractory cholestatic pruritus prior to the availability of <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a>. Sertraline was evaluated as adjunctive treatment in a prospective observational study in 20 children with refractory cholestatic pruritus, including 13 children with Alagille syndrome [<a href="#rid58">58</a>]. All participants were on maximal doses of UCDA and <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> at the start of the study and continued these medications during the study. After three months of therapy, pruritus, median itch score, skin scratch marks, and sleep quality improved with a tolerable side effect profile.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atorvastatin</strong> – <a class="drug drug_pediatric" data-topicid="12908" href="/z/d/drug information/12908.html" rel="external">Atorvastatin</a> is a lipid-lowering agent that is sometimes used for treatment of xanthomas in Alagille syndrome but rarely for pruritus. Pediatric data are limited to anecdotal reports. (See <a class="local">'Xanthomas'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bile acid sequestrants</strong> (eg, <a class="drug drug_pediatric" data-topicid="13152" href="/z/d/drug information/13152.html" rel="external">cholestyramine</a>, <a class="drug drug_pediatric" data-topicid="15550" href="/z/d/drug information/15550.html" rel="external">colesevelam</a>) – Bile acid sequestrants are now infrequently used for cholestatic pruritus due to their drug interactions, adverse effects, and tedious administration schedule. Colesevelam (Welchol) is available in pill form that may be more palatable than cholestyramine or other bile acid resins [<a href="#rid59">59</a>].</p><p></p><p>In historical series (prior to the availability of <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a>), pruritus was refractory to medical treatment in approximately 40 percent of affected patients. In these cases, surgical biliary diversion or liver transplantation may be indicated [<a href="#rid17">17,45,60</a>]. (See <a class="local">'Surgery'</a> below.)</p><p class="headingAnchor" id="H3985482371"><span class="h2">Xanthomas</span><span class="headingEndMark"> — </span>These lesions can form on areas with high friction when cholesterol levels are &gt;500 mg/dL and can be disfiguring. No specific treatment is required, as they typically resolve as cholestasis improves. However, anecdotal reports describe the use of statins in patients with severe, debilitating xanthomas with beneficial effects [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H237985516"><span class="h2">Fat-soluble vitamin deficiency</span><span class="headingEndMark"> — </span>Individuals with cholestasis (eg, direct bilirubin &gt;1 mg/dL) may have fat malabsorption due to insufficient bile acids in the bowel lumen, with associated fat-soluble vitamin deficiency. Monitoring and management of fat-soluble vitamin deficiency is similar to that in patients with biliary atresia  (<a class="graphic graphic_table graphicRef51569" href="/z/d/graphic/51569.html" rel="external">table 3</a>). Fixed-ratio multivitamin supplements (eg, DEKAs) are frequently used but may result in excessive intake of some vitamins when given in sufficient doses to treat insufficiency of other vitamins. In that case, vitamins may need to be dosed individually. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Fat-soluble vitamin supplements'</a>.)</p><p class="headingAnchor" id="H2113776279"><span class="h2">Nutrition</span><span class="headingEndMark"> — </span>Malnutrition, with associated growth failure, and pubertal delay are common in children with Alagille syndrome. The cause is likely multifactorial (malabsorption and/or the genetic defect) and should be treated proactively with high-energy supplements (often requiring nasogastric or gastrostomy feeding) and fat-soluble vitamin supplements. (See <a class="local">'Fat-soluble vitamin deficiency'</a> above.)</p><p>Pancreatic insufficiency appears to be uncommon in Alagille syndrome, so supplementation with pancreatic enzymes is unlikely to be an effective therapy for malnutrition [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H1065458005"><span class="h2">Liver disease progression</span><span class="headingEndMark"> — </span>Patients with persistent cholestatic liver disease sometimes develop progressive hepatic fibrosis and cirrhosis, which can lead to portal hypertension. Complications of portal hypertension include hypersplenism with related thrombocytopenia, esophageal varices with risk of variceal bleeding, and ascites.</p><p></p><p>Monitoring and management of the cirrhosis and portal hypertension are similar to that for biliary atresia and other chronic liver diseases, as discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Portal hypertension and variceal bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">"Portal hypertension in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H4095955533"><span class="h2">Hepatocellular carcinoma and hepatic nodules</span><span class="headingEndMark"> — </span>Hepatic lesions reported in Alagille syndrome include benign regenerative nodules (which usually do not require intervention) or hepatocellular carcinoma (HCC). Both types of lesions are reported, but their true incidence is unknown. HCC has been documented in both children and adults with a wide range of Alagille syndrome phenotypes and differing degrees of liver involvement [<a href="#rid62">62,63</a>]. Dysfunctional Notch signaling has been implicated in HCC and intrahepatic cholangiocarcinoma [<a href="#rid64">64</a>].</p><p>There is no consensus and considerable uncertainty regarding patient selection or protocols for screening for HCC. Common practice is to perform routine screening for individuals with advanced liver disease. Screening consists of close monitoring of liver enzymes, serial measurements of serum alpha-fetoprotein, and periodic ultrasound and advanced liver imaging, similar to protocols for children with hepatitis B virus infection (see  <a class="medical medical_review" href="/z/d/html/116139.html" rel="external">"Management of hepatitis B virus infection in children and adolescents", section on 'Hepatocellular carcinoma surveillance'</a>). However, the utility of routine screening is questionable because HCC is very rare (&lt;40 cases reported to date) [<a href="#rid62">62</a>]. Moreover, screening only people with advanced liver disease would miss the few cases that have been reported in individuals with mild liver disease, so further evidence is required to enable early detection and treatment in people with Alagille syndrome [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H2748917249"><span class="h2">Vascular anomalies</span><span class="headingEndMark"> — </span>Cerebral vascular anomalies are an important cause of morbidity due to intracranial bleeding, which occurs in up to one-quarter of individuals with Alagille syndrome [<a href="#rid24">24,25</a>]. Screening brain magnetic resonance imaging/magnetic resonance angiography is recommended in all Alagille syndrome patients when they reach an age where they do not require sedation for the examination. There should be a low threshold for brain imaging in the setting of head injury or neurologic symptoms. (See  <a class="medical medical_review" href="/z/d/html/1129.html" rel="external">"Vascular malformations of the central nervous system"</a> and  <a class="medical medical_review" href="/z/d/html/1087.html" rel="external">"Brain arteriovenous malformations"</a> and  <a class="medical medical_review" href="/z/d/html/1102.html" rel="external">"Posterior circulation cerebrovascular syndromes"</a>.)</p><p class="headingAnchor" id="H1790087254"><span class="h2">Cardiac and renal anomalies</span><span class="headingEndMark"> — </span>The extent of cardiac or renal disease and vascular anomalies is highly variable, and management is tailored to the involvement in the individual patient. Related UpToDate content includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong> – (See  <a class="medical medical_review" href="/z/d/html/14578.html" rel="external">"Pulmonic stenosis in infants and children: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/114558.html" rel="external">"Pulmonic stenosis in infants and children: Management and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/5770.html" rel="external">"Tetralogy of Fallot (TOF): Management and outcome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal</strong> – (See  <a class="medical medical_review" href="/z/d/html/6110.html" rel="external">"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p></p><p class="headingAnchor" id="H2570369493"><span class="h1">SURGERY</span><span class="headingEndMark"> — </span>Kasai hepatoportoenterostomy (HPE) is not recommended for individuals with Alagille syndrome. The procedure provides no added benefit for this population and, rather, may worsen outcomes (early liver transplantation or mortality) [<a href="#rid65">65</a>]. By contrast, HPE is a mainstay of treatment for biliary atresia. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Kasai procedure'</a>.)</p><p class="headingAnchor" id="H3247136109"><span class="h2">Biliary diversion</span><span class="headingEndMark"> — </span>A few case reports describe surgical biliary diversion or ileal resection for patients with Alagille syndrome and severe refractory cholestasis, with partial relief of symptoms [<a href="#rid60">60,66-69</a>]. Advances in medical treatment for pruritus, especially use of inhibitor of ileal bile acid transport (IBAT) inhibitors such as <a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a>, will very likely reduce the need for surgical biliary diversion.</p><p class="headingAnchor" id="H2338876703"><span class="h2">Liver transplantation</span><span class="headingEndMark"> — </span>In registry studies, more than one-half of individuals with hepatic manifestations of Alagille syndrome eventually required liver transplantation. (See <a class="local">'Natural history of liver disease'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for referral for transplant evaluation</strong> – Typical indications for liver transplant in Alagille syndrome include persistent cholestasis, complications of persistent cholestasis (intractable pruritus, growth failure, metabolic bone disease, fat-soluble vitamin deficiency), cirrhosis, and manifestations of portal hypertension (ascites, variceal bleeding requiring intervention) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretransplant evaluation</strong> – Pretransplant evaluation must include cardiac and renal assessments. Occasionally, individuals with Alagille syndrome require cardiac or renal transplant at the time of liver transplant. Cardiac disease should be repaired prior to liver transplant when possible. The extent of renal disease involvement may impact choice of post-transplant immunosuppression regimen. Other considerations include head and abdominal imaging to identify vascular anomalies, which could impact bleeding risk and technical aspects of the transplant procedure. (See <a class="local">'Cardiac and renal anomalies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Patient and graft survival one and five years after liver transplant have been reported to be lower for Alagille syndrome patients compared with biliary atresia patients, with one retrospective analysis showing a clustering of deaths for Alagille syndrome patients within the first 30 days [<a href="#rid70">70,71</a>]. Similar survival rates (five-year patient survival approximately 80 percent) are seen in Alagille syndrome patients receiving a living-related donor graft [<a href="#rid72">72</a>]. A more recent study from 2022, however, showed no difference in patient and graft survival between Alagille syndrome and biliary atresia [<a href="#rid73">73</a>]. Renal insufficiency in Alagille syndrome patients has been shown to worsen after liver transplant, supporting the need to follow renal-sparing immunosuppression protocols [<a href="#rid71">71</a>]. All potential living-related donors should undergo genetic testing, and any potential donor with a <em>JAG1</em> mutation should be eliminated from consideration, even if no overt liver disease is present [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H2166656707"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H2007162928"><span class="h2">Natural history of liver disease</span><span class="headingEndMark"> — </span>In large registry studies, more than one-half of individuals with hepatic manifestations of Alagille syndrome eventually required liver transplantation; the risk varied depending on the degree of cholestasis. In a cohort study (ChilLDReN) of 293 children with Alagille syndrome presenting with cholestasis, 24 percent survived to early adulthood with native liver [<a href="#rid37">37</a>]. Despite improvement of cholestasis, 40 percent of participants developed definite portal hypertension by 20 years of age. In another international cohort study (GALA Study Group) that included more than 1000 individuals with Alagille syndrome, 10- and 18-year native liver survival was 54 and 40 percent, respectively [<a href="#rid20">20</a>]. By 10 and 18 years, 51.5 and 66.0 percent of children with Alagille syndrome experienced ≥1 adverse liver-related event (clinically evident portal hypertension, transplant, or death), respectively. Children with a median total bilirubin level &lt;5 mg/dL at 6 to 12 months of age had higher rates of native liver survival, with 79 percent reaching adulthood with native liver. This contrasts with a 4.8-fold increased risk of liver transplant in children with a median total bilirubin level between ≥5 to &lt;10 mg/dL at 6 to 12 months of age [<a href="#rid20">20</a>].</p><p>If cholestasis is not present during childhood, it does not develop during adulthood. However, these individuals are still at risk for developing liver cancer, as described in a few case reports. (See <a class="local">'Hepatocellular carcinoma and hepatic nodules'</a> above.)</p><p>Notably, these studies reflect management prior to the availability of ileal bile acid transport (IBAT) inhibitors; whether use of these medications reduces the need for liver transplantation is an active area of research.</p><p>Individuals who are identified by screening family members of probands have substantially lower incidence of liver and cardiac disease. In one such cohort with <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601920&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoRWmEg%2BsEV5DEaSKoe5K9h&amp;TOPIC_ID=139432" target="_blank"><i>JAG1</i></a> variants, 55 percent had liver abnormalities, compared with 100 percent of probands [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2759775388"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>An early retrospective study of 92 individuals with Alagille syndrome determined that the factors that contributed significantly to mortality were complex congenital heart disease, intracranial bleeding, and hepatic disease or liver transplantation [<a href="#rid16">16</a>]. Overall mortality was 17 percent, with the major causes of death being hepatic death (average age 7.5 years), intracranial bleed (average age 2.9 years), and multisystem/cardiac failure (average age 1.6 years). The 20-year predicted life expectancy was 75 percent for all patients, 80 percent for those not requiring liver transplant, and 60 percent for those requiring liver transplant. In a more recent longitudinal cohort study (ChilLDReN) of 293 individuals with Alagille syndrome with native liver, 11 (4 percent) died with native liver during the study follow-up (median 2.7 years, range 0 to 10 years). Only three deaths were directly related to liver disease, with the remainder due to cardiac involvement, pulmonary hemorrhage, and "other" [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H1977024974"><span class="h1">RESOURCES</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fchildrennetwork.org%2F&amp;token=ZDjDmaDHHsBYgEVJXMeKLX0d%2B9A7ItvG2TZy7EcjxR%2BHawluUiRC2OmR9UeTxZFQ&amp;TOPIC_ID=139432" target="_blank">Childhood Liver Disease Research Network</a> (ChilDReN)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Falagille.org%2F&amp;token=D2EEVdVaGngmEPU794gNCpGm2yzW93%2FEDXTxMjrD4Us%3D&amp;TOPIC_ID=139432" target="_blank">Alagille Syndrome Alliance</a></p><p class="bulletIndent1"><span class="glyph">●</span>Global Alagille Alliance (GALA) Study Group</p><p></p><p class="headingAnchor" id="H1610553638"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116507.html" rel="external">"Society guideline links: Pediatric liver disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116513.html" rel="external">"Society guideline links: Neonatal jaundice"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116713.html" rel="external">"Society guideline links: Inherited liver disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114698.html" rel="external">"Society guideline links: Portal hypertension and ascites"</a>.)</p><p class="headingAnchor" id="H2735646031"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathogenesis</strong> – Alagille syndrome is an autosomal dominant disorder, usually caused by pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601920&amp;token=87jLzclRwWxNoI%2BQq5Gg774xSAoGh1xfv48zrsTU3sqguhOZACU1cxJ%2FJwdr%2BZkS&amp;TOPIC_ID=139432" target="_blank"><i>JAG1</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600275&amp;token=87jLzclRwWxNoI%2BQq5Gg71ccfWEtTEKgWzBy1w8isFuHtnp%2FqS2XEbs6LYvN1tod&amp;TOPIC_ID=139432" target="_blank"><i>NOTCH2</i></a> genes. (See <a class="local">'Genetics and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Alagille syndrome affects multiple organ systems and has a wide range of clinical severity. The most clinically important manifestations are cholestatic liver disease, congenital heart disease, and cerebrovascular anomalies  (<a class="graphic graphic_table graphicRef141282" href="/z/d/graphic/141282.html" rel="external">table 1</a>). Other common features include characteristic facies  (<a class="graphic graphic_picture graphicRef53349" href="/z/d/graphic/53349.html" rel="external">picture 1</a>), renal disease, ocular abnormalities, skeletal abnormalities, and growth failure. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Alagille syndrome is suspected in individuals who present with suggestive features (especially otherwise unexplained cholestatic liver disease) or those with a parent or sibling with Alagille syndrome. The sequence and pace of the evaluation depends on the individual patient. For young infants who present with cholestatic liver disease, the first priority is to evaluate for biliary atresia. For family members of an individual with Alagille syndrome, the first step is genetic testing. Those with suspected or confirmed Alagille syndrome should have a full evaluation for associated anomalies. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of Alagille syndrome should be confirmed by genetic testing whenever possible. Occasionally, the diagnosis is made based on clinical criteria alone. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Medical management of patients with Alagille syndrome is tailored to the patient's disease manifestations and severity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver disease</strong> – Cholestatic liver disease often requires intensive management for:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pruritus, which can be debilitating. It is initially managed with medications  (<a class="graphic graphic_table graphicRef141283" href="/z/d/graphic/141283.html" rel="external">table 2</a>) and may be an indication for liver transplantation. For most patients with pruritus, we suggest initial treatment with <a class="drug drug_pediatric" data-topicid="12872" href="/z/d/drug information/12872.html" rel="external">ursodeoxycholic acid</a> (UDCA) and an antihistamine as needed rather than other drugs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For refractory pruritus, add-on medications may include ileal bile acid transport (IBAT) inhibitors (<a class="drug drug_pediatric" data-topicid="133174" href="/z/d/drug information/133174.html" rel="external">maralixibat</a> or <a class="drug drug_pediatric" data-topicid="132117" href="/z/d/drug information/132117.html" rel="external">odevixibat</a>), <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a>, and/or <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>. (See <a class="local">'Pruritus'</a> above and <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Fat malabsorption, with fat-soluble vitamin deficiencies, which requires monitoring and vitamin replacement  (<a class="graphic graphic_table graphicRef51569" href="/z/d/graphic/51569.html" rel="external">table 3</a>). (See <a class="local">'Nutrition'</a> above and <a class="local">'Fat-soluble vitamin deficiency'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cirrhosis with portal hypertension, hypersplenism, ascites, and esophageal varices with risk of variceal bleeding. Management is similar to that for other causes of portal hypertension and may include liver transplantation. (See <a class="local">'Liver disease progression'</a> above and <a class="local">'Liver transplantation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Risk for hepatocellular carcinoma (HCC). Common practice is to monitor for HCC in individuals with advanced liver disease, but there is no consensus on patient selection or monitoring protocols. (See <a class="local">'Hepatocellular carcinoma and hepatic nodules'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vascular</strong> <strong>anomalies</strong> – Cerebral vascular anomalies are an important cause of morbidity due to intracranial bleeding, which occurs in up to one-quarter of individuals with Alagille syndrome. All patients should be screened with advanced brain imaging and evaluated promptly if they develop concerning symptoms. (See <a class="local">'Vascular anomalies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – Management of congenital heart disease and renal anomalies is similar to that for individuals without Alagille syndrome. (See  <a class="medical medical_review" href="/z/d/html/114558.html" rel="external">"Pulmonic stenosis in infants and children: Management and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/5770.html" rel="external">"Tetralogy of Fallot (TOF): Management and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/6110.html" rel="external">"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kamath BM, Bason L, Piccoli DA, et al. Consequences of JAG1 mutations. J Med Genet 2003; 40:891.</a></li><li class="breakAll">Spinner NB, Gilbert MA, Loomes KM, et al. Alagille Syndrome. 2000 May 19 [Updated 2019 Dec 12]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1273/ (Accessed on August 23, 2022).</li><li><a class="nounderline abstract_t">Gilbert MA, Bauer RC, Rajagopalan R, et al. Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum Mutat 2019; 40:2197.</a></li><li><a class="nounderline abstract_t">Oda T, Elkahloun AG, Pike BL, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997; 16:235.</a></li><li><a class="nounderline abstract_t">Spinner NB, Colliton RP, Crosnier C, et al. Jagged1 mutations in alagille syndrome. Hum Mutat 2001; 17:18.</a></li><li><a class="nounderline abstract_t">Crosnier C, Driancourt C, Raynaud N, et al. Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome. Gastroenterology 1999; 116:1141.</a></li><li><a class="nounderline abstract_t">McDaniell R, Warthen DM, Sanchez-Lara PA, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 2006; 79:169.</a></li><li><a class="nounderline abstract_t">Kamath BM, Bauer RC, Loomes KM, et al. NOTCH2 mutations in Alagille syndrome. J Med Genet 2012; 49:138.</a></li><li><a class="nounderline abstract_t">Tsai EA, Gilbert MA, Grochowski CM, et al. THBS2 Is a Candidate Modifier of Liver Disease Severity in Alagille Syndrome. Cell Mol Gastroenterol Hepatol 2016; 2:663.</a></li><li><a class="nounderline abstract_t">Ryan MJ, Bales C, Nelson A, et al. Bile duct proliferation in Jag1/fringe heterozygous mice identifies candidate modifiers of the Alagille syndrome hepatic phenotype. Hepatology 2008; 48:1989.</a></li><li><a class="nounderline abstract_t">Thakurdas SM, Lopez MF, Kakuda S, et al. Jagged1 heterozygosity in mice results in a congenital cholangiopathy which is reversed by concomitant deletion of one copy of Poglut1 (Rumi). Hepatology 2016; 63:550.</a></li><li><a class="nounderline abstract_t">Adams JM, Huppert KA, Castro EC, et al. Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome. Hepatology 2020; 71:1331.</a></li><li><a class="nounderline abstract_t">Rajagopalan R, Gilbert MA, McEldrew DA, et al. Genome sequencing increases diagnostic yield in clinically diagnosed Alagille syndrome patients with previously negative test results. Genet Med 2021; 23:323.</a></li><li><a class="nounderline abstract_t">Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 2001; 49:431.</a></li><li><a class="nounderline abstract_t">Alagille D, Estrada A, Hadchouel M, et al. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987; 110:195.</a></li><li><a class="nounderline abstract_t">Emerick KM, Rand EB, Goldmuntz E, et al. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999; 29:822.</a></li><li><a class="nounderline abstract_t">Kamath BM, Baker A, Houwen R, et al. Systematic Review: The Epidemiology, Natural History, and Burden of Alagille Syndrome. J Pediatr Gastroenterol Nutr 2018; 67:148.</a></li><li><a class="nounderline abstract_t">Subramaniam P, Knisely A, Portmann B, et al. Diagnosis of Alagille syndrome-25 years of experience at King's College Hospital. J Pediatr Gastroenterol Nutr 2011; 52:84.</a></li><li><a class="nounderline abstract_t">Kamath BM, Munoz PS, Bab N, et al. A longitudinal study to identify laboratory predictors of liver disease outcome in Alagille syndrome. J Pediatr Gastroenterol Nutr 2010; 50:526.</a></li><li><a class="nounderline abstract_t">Vandriel SM, Li LT, She H, et al. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study. Hepatology 2023; 77:512.</a></li><li><a class="nounderline abstract_t">Kahn E. Paucity of interlobular bile ducts. Arteriohepatic dysplasia and nonsyndromic duct paucity. Perspect Pediatr Pathol 1991; 14:168.</a></li><li><a class="nounderline abstract_t">McElhinney DB, Krantz ID, Bason L, et al. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation 2002; 106:2567.</a></li><li><a class="nounderline abstract_t">Kamath BM, Spinner NB, Emerick KM, et al. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation 2004; 109:1354.</a></li><li><a class="nounderline abstract_t">Emerick KM, Krantz ID, Kamath BM, et al. Intracranial vascular abnormalities in patients with Alagille syndrome. J Pediatr Gastroenterol Nutr 2005; 41:99.</a></li><li><a class="nounderline abstract_t">Carpenter CD, Linscott LL, Leach JL, et al. Spectrum of cerebral arterial and venous abnormalities in Alagille syndrome. Pediatr Radiol 2018; 48:602.</a></li><li><a class="nounderline abstract_t">Kamath BM, Podkameni G, Hutchinson AL, et al. Renal anomalies in Alagille syndrome: a disease-defining feature. Am J Med Genet A 2012; 158A:85.</a></li><li><a class="nounderline abstract_t">Sanderson E, Newman V, Haigh SF, et al. Vertebral anomalies in children with Alagille syndrome: an analysis of 50 consecutive patients. Pediatr Radiol 2002; 32:114.</a></li><li><a class="nounderline abstract_t">Okuno T, Takahashi H, Shibahara Y, et al. Temporal bone histopathologic findings in Alagille's syndrome. Arch Otolaryngol Head Neck Surg 1990; 116:217.</a></li><li><a class="nounderline abstract_t">Bales CB, Kamath BM, Munoz PS, et al. Pathologic lower extremity fractures in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 2010; 51:66.</a></li><li><a class="nounderline abstract_t">Kamath BM, Stolle C, Bason L, et al. Craniosynostosis in Alagille syndrome. Am J Med Genet 2002; 112:176.</a></li><li><a class="nounderline abstract_t">Yilmaz S, Turhan T, Mutluer S, Aydogdu S. The association of Alagille syndrome and craniosynostosis. Pediatr Neurol 2013; 48:146.</a></li><li><a class="nounderline abstract_t">Kamath BM, Loomes KM, Oakey RJ, et al. Facial features in Alagille syndrome: specific or cholestasis facies? Am J Med Genet 2002; 112:163.</a></li><li><a class="nounderline abstract_t">Hingorani M, Nischal KK, Davies A, et al. Ocular abnormalities in Alagille syndrome. Ophthalmology 1999; 106:330.</a></li><li><a class="nounderline abstract_t">Rock NM, Demaret T, Stéphenne X, et al. Intracranial Hypertension and Papilledema in a Large Cohort of Pediatric Patients With Alagille Syndrome. J Pediatr Gastroenterol Nutr 2020; 71:655.</a></li><li><a class="nounderline abstract_t">Rovner AJ, Schall JI, Jawad AF, et al. Rethinking growth failure in Alagille syndrome: the role of dietary intake and steatorrhea. J Pediatr Gastroenterol Nutr 2002; 35:495.</a></li><li><a class="nounderline abstract_t">Bucuvalas JC, Horn JA, Carlsson L, et al. Growth hormone insensitivity associated with elevated circulating growth hormone-binding protein in children with Alagille syndrome and short stature. J Clin Endocrinol Metab 1993; 76:1477.</a></li><li><a class="nounderline abstract_t">Kamath BM, Ye W, Goodrich NP, et al. Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study. Hepatol Commun 2020; 4:387.</a></li><li><a class="nounderline abstract_t">Leung DH, Sorensen LG, Ye W, et al. Neurodevelopmental Outcomes in Children With Inherited Liver Disease and Native Liver. J Pediatr Gastroenterol Nutr 2022; 74:96.</a></li><li><a class="nounderline abstract_t">Elisofon SA, Emerick KM, Sinacore JM, Alonso EM. Health status of patients with Alagille syndrome. J Pediatr Gastroenterol Nutr 2010; 51:759.</a></li><li><a class="nounderline abstract_t">Kamath BM, Chen Z, Romero R, et al. Quality of Life and Its Determinants in a Multicenter Cohort of Children with Alagille Syndrome. J Pediatr 2015; 167:390.</a></li><li><a class="nounderline abstract_t">Vandriel S, Li L, She H, et al. Phenotypic divergence of JAGGED1 and NOTCH2-associated Alagille syndrome: results from the International Multicenter GALA Study Group. Hepatology 2020; 72:882A.</a></li><li class="breakAll">Spinner NB, Leonard LD, Krantz ID. Alagille Syndrome. 2000 May 19 [Updated 2013 Feb 28]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. http://www.ncbi.nlm.nih.gov/books/NBK1273/ (Accessed on August 19, 2015).</li><li><a class="nounderline abstract_t">Yehezkely-Schildkraut V, Munichor M, Mandel H, et al. Nonsyndromic paucity of interlobular bile ducts: report of 10 patients. J Pediatr Gastroenterol Nutr 2003; 37:546.</a></li><li><a class="nounderline abstract_t">Kamath BM, Loomes KM, Piccoli DA. Medical management of Alagille syndrome. J Pediatr Gastroenterol Nutr 2010; 50:580.</a></li><li><a class="nounderline abstract_t">Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in paediatric patients with alagille syndrome: the King's College Hospital experience. J Pediatr Gastroenterol Nutr 2013; 57:149.</a></li><li><a class="nounderline abstract_t">Narkewicz MR, Smith D, Gregory C, et al. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998; 26:49.</a></li><li><a class="nounderline abstract_t">Yerushalmi B, Sokol RJ, Narkewicz MR, et al. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999; 29:442.</a></li><li class="breakAll">Manufacturer's prescribing information for maralixibat (LIVMARLI), 3/2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214662s004lbl.pdf (Accessed on March 27, 2023).</li><li><a class="nounderline abstract_t">Shneider BL, Spino CA, Kamath BM, et al. Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome. Hepatol Commun 2022; 6:1922.</a></li><li><a class="nounderline abstract_t">Hansen BE, Vandriel SM, Vig P, et al. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA. Hepatology 2023.</a></li><li><a class="nounderline abstract_t">Sokol RJ, Gonzales EM, Kamath BM, et al. Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor. Hepatology 2023; 78:1698.</a></li><li><a class="nounderline abstract_t">Baumann U, Sturm E, Lacaille F, et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. Clin Res Hepatol Gastroenterol 2021; 45:101751.</a></li><li class="breakAll">Manufacturer's prescibing information for BYLVAY (odevixibat), June 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215498s003lbl.pdf (Accessed on July 05, 2023).</li><li><a class="nounderline abstract_t">Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J Pediatr Gastroenterol Nutr 2010; 51:787.</a></li><li><a class="nounderline abstract_t">Chang Y, Golkar L. The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case. Pediatr Dermatol 2008; 25:403.</a></li><li><a class="nounderline abstract_t">Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12:1125.</a></li><li><a class="nounderline abstract_t">Terg R, Coronel E, Sordá J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37:717.</a></li><li><a class="nounderline abstract_t">Thébaut A, Habes D, Gottrand F, et al. Sertraline as an Additional Treatment for Cholestatic Pruritus in Children. J Pediatr Gastroenterol Nutr 2017; 64:431.</a></li><li><a class="nounderline abstract_t">Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. Am J Health Syst Pharm 2007; 64:1157.</a></li><li><a class="nounderline abstract_t">Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002; 35:1501.</a></li><li><a class="nounderline abstract_t">Kamath BM, Piccoli DA, Magee JC, et al. Pancreatic insufficiency is not a prevalent problem in Alagille syndrome. J Pediatr Gastroenterol Nutr 2012; 55:612.</a></li><li><a class="nounderline abstract_t">Schindler EA, Gilbert MA, Piccoli DA, et al. Alagille syndrome and risk for hepatocellular carcinoma: Need for increased surveillance in adults with mild liver phenotypes. Am J Med Genet A 2021; 185:719.</a></li><li><a class="nounderline abstract_t">Bhadri VA, Stormon MO, Arbuckle S, et al. Hepatocellular carcinoma in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 2005; 41:676.</a></li><li><a class="nounderline abstract_t">Lu J, Xia Y, Chen K, et al. Oncogenic role of the Notch pathway in primary liver cancer. Oncol Lett 2016; 12:3.</a></li><li><a class="nounderline abstract_t">Kaye AJ, Rand EB, Munoz PS, et al. Effect of Kasai procedure on hepatic outcome in Alagille syndrome. J Pediatr Gastroenterol Nutr 2010; 51:319.</a></li><li><a class="nounderline abstract_t">Durgin JM, Crum R, Kim HB, Cuenca AG. Outcomes of internal biliary diversion using cholecystocolostomy for patients with severe Alagille syndrome. J Surg Case Rep 2022; 2022:rjac307.</a></li><li><a class="nounderline abstract_t">Mattei P, von Allmen D, Piccoli D, Rand E. Relief of intractable pruritus in Alagille syndrome by partial external biliary diversion. J Pediatr Surg 2006; 41:104.</a></li><li><a class="nounderline abstract_t">Modi BP, Suh MY, Jonas MM, et al. Ileal exclusion for refractory symptomatic cholestasis in Alagille syndrome. J Pediatr Surg 2007; 42:800.</a></li><li><a class="nounderline abstract_t">Wang KS, Tiao G, Bass LM, et al. Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology 2017; 65:1645.</a></li><li><a class="nounderline abstract_t">Arnon R, Annunziato R, Miloh T, et al. Orthotopic liver transplantation for children with Alagille syndrome. Pediatr Transplant 2010; 14:622.</a></li><li><a class="nounderline abstract_t">Kamath BM, Yin W, Miller H, et al. Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience. Liver Transpl 2012; 18:940.</a></li><li><a class="nounderline abstract_t">Kasahara M, Kiuchi T, Inomata Y, et al. Living-related liver transplantation for Alagille syndrome. Transplantation 2003; 75:2147.</a></li><li><a class="nounderline abstract_t">Black K, Ziogas IA, Thurm C, et al. Pediatric Liver Transplant Survival in Alagille Syndrome Is Comparable to Biliary Atresia-A Linked Database Analysis. J Pediatr Gastroenterol Nutr 2022; 75:257.</a></li></ol></div><div id="topicVersionRevision">Topic 139432 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684686" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Consequences of JAG1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684686" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Consequences of JAG1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31343788" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207787" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mutations in the human Jagged1 gene are responsible for Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11139239" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Jagged1 mutations in alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10220506" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16773578" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22209762" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : NOTCH2 mutations in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28090565" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : THBS2 Is a Candidate Modifier of Liver Disease Severity in Alagille Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026002" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bile duct proliferation in Jag1/fringe heterozygous mice identifies candidate modifiers of the Alagille syndrome hepatic phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26235536" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Jagged1 heterozygosity in mice results in a congenital cholangiopathy which is reversed by concomitant deletion of one copy of Poglut1 (Rumi).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31469182" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33077891" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genome sequencing increases diagnostic yield in clinically diagnosed Alagille syndrome patients with previously negative test results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511567" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Outcome of liver disease in children with Alagille syndrome: a study of 163 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3806290" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051485" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Features of Alagille syndrome in 92 patients: frequency and relation to prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29543694" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Systematic Review: The Epidemiology, Natural History, and Burden of Alagille Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21119543" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnosis of Alagille syndrome-25 years of experience at King's College Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421762" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A longitudinal study to identify laboratory predictors of liver disease outcome in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36036223" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2038547" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Paucity of interlobular bile ducts. Arteriohepatic dysplasia and nonsyndromic duct paucity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427653" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993126" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990638" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intracranial vascular abnormalities in patients with Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29362841" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Spectrum of cerebral arterial and venous abnormalities in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105858" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal anomalies in Alagille syndrome: a disease-defining feature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11819079" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vertebral anomalies in children with Alagille syndrome: an analysis of 50 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2297420" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Temporal bone histopathologic findings in Alagille's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453673" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pathologic lower extremity fractures in children with Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12244552" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Craniosynostosis in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23337010" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The association of Alagille syndrome and craniosynostosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12244550" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Facial features in Alagille syndrome: specific or cholestasis facies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9951486" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ocular abnormalities in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33093373" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intracranial Hypertension and Papilledema in a Large Cohort of Pediatric Patients With Alagille Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12394373" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rethinking growth failure in Alagille syndrome: the role of dietary intake and steatorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501153" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Growth hormone insensitivity associated with elevated circulating growth hormone-binding protein in children with Alagille syndrome and short stature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33313463" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34694263" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neurodevelopmental Outcomes in Children With Inherited Liver Disease and Native Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20948445" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Health status of patients with Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26059338" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Quality of Life and Its Determinants in a Multicenter Cohort of Children with Alagille Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Phenotypic divergence of JAGGED1 and NOTCH2-associated Alagille syndrome: results from the International Multicenter GALA Study Group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Phenotypic divergence of JAGGED1 and NOTCH2-associated Alagille syndrome: results from the International Multicenter GALA Study Group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581794" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nonsyndromic paucity of interlobular bile ducts: report of 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479679" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Medical management of Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23619030" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Management of cholestatic pruritus in paediatric patients with alagille syndrome: the King's College Hospital experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443120" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10512405" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of rifampin for severe pruritus in children with chronic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10512405" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of rifampin for severe pruritus in children with chronic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35672955" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38146932" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37278241" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34182185" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34182185" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20948447" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18577062" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534857" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of oral naltrexone on pruritus in cholestatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12445410" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27557426" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sertraline as an Additional Treatment for Cholestatic Pruritus in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519457" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of cholestatic pruritus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12029636" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614108" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pancreatic insufficiency is not a prevalent problem in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33369123" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Alagille syndrome and risk for hepatocellular carcinoma: Need for increased surveillance in adults with mild liver phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254531" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hepatocellular carcinoma in children with Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27347091" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Oncogenic role of the Notch pathway in primary liver cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20601899" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of Kasai procedure on hepatic outcome in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35794995" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Outcomes of internal biliary diversion using cholecystocolostomy for patients with severe Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16410117" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Relief of intractable pruritus in Alagille syndrome by partial external biliary diversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502187" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ileal exclusion for refractory symptomatic cholestasis in Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027587" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20070561" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Orthotopic liver transplantation for children with Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22454296" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829928" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Living-related liver transplantation for Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35696710" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pediatric Liver Transplant Survival in Alagille Syndrome Is Comparable to Biliary Atresia-A Linked Database Analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
